Similar articles for PMID: 4823268

Year	Number of Results
1972	1
1974	1
1979	2
1980	4
1981	1
1982	1
1983	4
1985	3
1986	1
1992	1
1993	2
1994	1
1995	2
1996	2
1997	1
1999	1
2000	1
2001	1
2002	1
2003	2
2004	2
2005	1
2006	1
2008	1
2009	1
2021	1
2024	0

1

Distribution and retention of the antitumor agent 195mPt-cis-dichlorodiammine platinum (II) in man.

Smith HS, Taylor DM. Smith HS, et al. J Nucl Med. 1974 May;15(5):349-51. J Nucl Med. 1974. PMID: 4823268 Free article. No abstract available.

2

Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.

Yoshida M, Khokhar AR, Siddik ZH. Yoshida M, et al. Cancer Res. 1994 Jul 1;54(13):3468-73. Cancer Res. 1994. PMID: 8012968

3

Organo-platinum complexes as antitumor agents (review).

Hill JM, Speer RJ. Hill JM, et al. Anticancer Res. 1982 May-Jun;2(3):173-86. Anticancer Res. 1982. PMID: 6751211 Review.

4

In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera.

Owens SE, Thatcher N, Sharma H, Adam N, Harrison R, Smith A, Zaki A, Baer JC, McAuliffe CA, Crowther D, et al. Owens SE, et al. Cancer Chemother Pharmacol. 1985;14(3):253-7. doi: 10.1007/BF00258128. Cancer Chemother Pharmacol. 1985. PMID: 3888431

5

cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.

Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR. Raynaud FI, et al. Clin Cancer Res. 1997 Nov;3(11):2063-74. Clin Cancer Res. 1997. PMID: 9815598

6

A comparative study of the distribution in the male rat of platinum-labelled cis-dichlorodiammine platinum (II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (I), and cis-dichloro-bis-cyclopropylamine platinum (II).

Harrison R, McAuliffe CA, Zaki A, Baer J, Sharma H, Smith A, Jackson H, Fox BW. Harrison R, et al. Cancer Chemother Pharmacol. 1983;10(2):90-5. doi: 10.1007/BF00446216. Cancer Chemother Pharmacol. 1983. PMID: 6682017 No abstract available.

7

Preparation and metabolism of a cisplatin/serum protein complex.

Cole WC, Wolf W. Cole WC, et al. Chem Biol Interact. 1980 May;30(2):223-35. doi: 10.1016/0009-2797(80)90128-3. Chem Biol Interact. 1980. PMID: 7190078

8

Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues.

Kasparkova J, Novakova O, Najajreh Y, Gibson D, Perez JM, Brabec V. Kasparkova J, et al. Chem Res Toxicol. 2003 Nov;16(11):1424-32. doi: 10.1021/tx034128g. Chem Res Toxicol. 2003. PMID: 14615968

9

Potential effects of edema on the pharmacokinetics of platinum in patients treated with cis-dichlorodiammine platinum (II).

Buice RG, Soloway MS. Buice RG, et al. Res Commun Chem Pathol Pharmacol. 1980 Dec;30(3):447-57. Res Commun Chem Pathol Pharmacol. 1980. PMID: 7196063

10

Role of carrier ligand in platinum resistance of human carcinoma cell lines.

Schmidt W, Chaney SG. Schmidt W, et al. Cancer Res. 1993 Feb 15;53(4):799-805. Cancer Res. 1993. PMID: 8428361

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

40 results

Results by year